CClinicalTrials.gg
Status unknownNCT02153021Updated Jun 2, 2014

New Therapeutic Perspectives in Obesity

A Phase 1 interventional study of Phototherapy in Obesity;, sponsored by Universidade Federal de Sao Carlos. Status unknown at 1 site in Brazil. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2014-06-02.

Sponsored by Universidade Federal de Sao Carlos · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2014), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Obesity is a chronic disease of increasing prevalence, being currently considered a global epidemic, including children, adolescents, adults and the elderly of different nationalities and ethnicities, socioeconomic levels, education levels. Non-pharmacological therapeutic interventions, such as physical exercise and fitness healthy eating strategies seem to be increasingly studied and recommended for healthy weight loss. In addition, therapies that can complement the effect of exercise and diet for reducing body weight are considerate important strategies. Thus, experimental evidence shows that the use of laser therapy combined with exercise swimming was effective in controlling the lipid profile, reducing the mass of adipose tissue, suggesting increased metabolic activity and changes in lipid metabolism.

To investigate the effect of the use of therapeutic laser when associated to exercise like response to new therapy for weight loss and decrease of dyslipidemias levels.

Read the detailed description

Methods:

During 20 weeks, each patients will receive 3 session of exercise with duration of 1 hour. Each session of exercise will composed of aerobic exercise and resistence exercise. After training session, each patient will receive application of phototherapy during 16 minutes. The protocol of phototherapy appplication is described in link "interventions"

02

Conditions studied

  • Obesity;

Browse trials for

Keywords

  • anthropometric parameters;
  • biochemical parameters;
  • inflammatory markers
  • neuropeptide markers
  • phototherapy
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's planned enrollment of 64 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Universidade Federal de Sao Carlos is the lead sponsor of 85 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • volunteers aged 20-40 years with a body mass index (BMI) ≥ 30 above, of both genders with primary obesity;

Exclusion criteria

Exclusion Criteria:

  • The criteria for inclusion are volunteers who use contraceptive use, cortisone, anti-epileptic drugs, history of kidney and heart disease, alcohol abuse, smoking, use of supplemental vitamins or secondary diagnosis of obesity.

After the pre-selection in the initial interview, the volunteers who contemplate all the inclusion criteria will be referred for clinical evaluation with an interdisciplinary health team and the electrocardiogram stress test to verify the release of the practice of physical exercises proposed by the project .

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
64 participants (estimated)

Study arms

  • Placebo comparator
    Lifestyle counseling

    alimentation information: a nutritionist provides nutritional orientation; exercise training: 3 days by week the patients will have specific sessions of resistance training (30 minutes) and aerobic training (30 minutes); phototherapy: all patients will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral. In Sham group,the equipment will be off.

  • Active comparator
    Phototherapy

    phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral. Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J

    Radiation: Phototherapy

Interventions

  • RadiationPhototherapy

    phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral. Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J

    Also known as: laser, lasertherapy, low-level laser therapy

06

What researchers measure

Primary outcomes

  1. Anthropometric measure

    Weight body: this measure would occurs during each week.

    Time frame: the measure occur up to 20 weeks

  2. anthropometric parameter

    total body fat: this measure would occurs during each week

    Time frame: the measure occur up to 20 weeks

  3. anthropometric parameter

    visceral body fat: this measure would occurs during each week

    Time frame: the measure occur up to 20 weeks

  4. anthropometric parameter

    total muscle

    Time frame: the measure occur up to 20 weeks

Secondary outcomes

  1. Primary biochemical analyzes

    The primary biochemical: glicemic variables (glucose and insulin)

    Time frame: the measures occur up to 20 weeks

  2. Primary biochemical analyzes

    the lipids variables (total cholesterol; triglycerides; low density lipoprotein; very low density lipoprotein; high density lipoprotein)

    Time frame: the measure occur up to 20 weeks

Other outcomes

  1. measure of neuropeptide

    neuropeptides variables: neuropeptide Y (NPY); agouti-related peptide (agRP); melanotropic hormone (MCH); Leptine; alpha melanocyte stimulating (alpha MSH); Pro-opiomelanocortin (POMC); Cocaine-Amphetamine-Regulated Transcript (CART);

    Time frame: measures up to 20 weeks

  2. measure of interleukines and citokines

    interleukines and citokines variables: iL-1; iL-4; iL-6; iL-10; c reactive protein.

    Time frame: the measure occur up to 20 weeks

07

Study locations

1 site
  • Unversidade Federal de São Carlos
    São Carlos, São Paulo 13565905, Brazil
    • Antonio E de AquinoJunior, Master · Contact · antonioaquino@ursa.ifsc.usp.br · +55XX16991721127
    • Antonio E de Aquino Junior, Master · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02153021
Lead sponsor
Universidade Federal de Sao Carlos
Collaborators
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Fundação de Amparo à Pesquisa do Estado de São Paulo
Responsible party
Nivaldo Antonio Parizotto (PhD, Universidade Federal de Sao Carlos) — Principal investigator
First posted
Jun 2, 2014
Start date
Sep 2014
Primary completion
Dec 2014 (estimated)
Completion
Feb 2015 (estimated)
Last update
Jun 2, 2014

Study contacts

Nivaldo A Parizotto, PhD
principal investigator · Universidade Federal de Sao Carlos

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion